Intranasal neuropeptide Y1 receptor antagonism improves motor deficits in symptomatic SOD1 ALS mice

4Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objective: Neuropeptide Y (NPY) is a 36 amino acid peptide widely considered to provide neuroprotection in a range of neurodegenerative diseases. In the fatal motor neuron disease amyotrophic lateral sclerosis (ALS), recent evidence supports a link between NPY and ALS disease processes. The goal of this study was to determine the therapeutic potential and role of NPY in ALS, harnessing the brain-targeted intranasal delivery of the peptide, previously utilised to correct motor and cognitive phenotypes in other neurological conditions. Methods: To confirm the association with clinical disease characteristics, NPY expression was quantified in post-mortem motor cortex tissue of ALS patients and age-matched controls. The effect of NPY on ALS cortical pathophysiology was investigated using slice electrophysiology and multi-electrode array recordings of SOD1G93A cortical cultures in vitro. The impact of NPY on ALS disease trajectory was investigated by treating SOD1G93A mice intranasally with NPY and selective NPY receptor agonists and antagonists from pre-symptomatic and symptomatic phases of disease. Results: In the human post-mortem ALS motor cortex, we observe a significant increase in NPY expression, which is not present in the somatosensory cortex. In vitro, we demonstrate that NPY can ameliorate ALS hyperexcitability, while brain-targeted nasal delivery of NPY and a selective NPY Y1 receptor antagonist modified survival and motor deficits specifically within the symptomatic phase of the disease in the ALS SOD1G93A mouse. Interpretation: Taken together, these findings highlight the capacity for non-invasive brain-targeted interventions in ALS and support antagonism of NPY Y1Rs as a novel strategy to improve ALS motor function.

References Powered by Scopus

Neuropeptide Y distribution in human brain

650Citations
N/AReaders
Get full text

Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis

390Citations
N/AReaders
Get full text

Functional changes in neuropeptide Y- and somatostatin-containing neurons induced by limbic seizures in the rat

238Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Novel approaches to assessing upper motor neuron dysfunction in motor neuron disease/amyotrophic lateral sclerosis: IFCN handbook chapter

6Citations
N/AReaders
Get full text

Distinct neuronal circuits mediate cortical hyperexcitability in amyotrophic lateral sclerosis

4Citations
N/AReaders
Get full text

Alterations to metabolic hormones in amyotrophic lateral sclerosis and frontotemporal dementia postmortem human tissue

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Clark, R. M., Clark, C. M., Lewis, K. E. A., Dyer, M. S., Chuckowree, J. A., Hoyle, J. A., … Dickson, T. C. (2023). Intranasal neuropeptide Y1 receptor antagonism improves motor deficits in symptomatic SOD1 ALS mice. Annals of Clinical and Translational Neurology, 10(11), 1985–1999. https://doi.org/10.1002/acn3.51885

Readers over time

‘24036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

67%

Researcher 1

33%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 1

25%

Neuroscience 1

25%

Agricultural and Biological Sciences 1

25%

Medicine and Dentistry 1

25%

Article Metrics

Tooltip
Mentions
News Mentions: 2

Save time finding and organizing research with Mendeley

Sign up for free
0